Clinical trials: MG - Myasthenia Gravis
Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD)
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory autoimmune diseases.
- Conditions
- Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD), Progressive Multiple Sclerosis (PMS), Relapsed/Refractory Myasthenia Gravis(r/r MS)
- Trial name
- NCT07583030
- Testing
- LVIVO-TaVec400 product
- Where
- 4 sites in China
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Myasthenia Gravis
Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis
This study is a double-blind, placebo-controlled, randomized clinical trial to determine whether IVIG is effective in improving motor scores in patients with myasthenia gravis and worsening weakness.
- Trial name
- NCT00306033
- Testing
- Intravenous ImmuneGlobulin
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University Health Network, Toronto
Lambert-Eaton Myasthenic Syndrome
Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
The purpose of the study is to provide expanded access (compassionate use) of 3,4 diaminopyridine to patients with Lambert-Eaton myasthenic syndrome (LEMS).
- Trial name
- NCT00994916
- Testing
- 3,4 diaminopyridine
- Sponsor
- David Lacomis, MD
Generalized Myasthenia Gravis
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
- Trial name
- NCT07039916
- Testing
- IMVT-1402
- Where
- 88 sites in United States, Argentina and 13 more
- Volunteers
- 231 people
- Sponsor
- Immunovant Sciences GmbH
Myasthenia Gravis, Autoimmune Diseases
Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis
This study is designed to explore the efficacy and safety of Telitacicept combined with low-dose steroids for the treatment of refractory MG, and to investigate related biomarkers such as immunoglobulins, BlyS/APRIL, and AChR-Ab…
- Trial name
- NCT06723548
- Testing
- Telitacicept
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Myasthenia Gravis
Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
The purpose of this trial is to determine if thymectomy combined with prednisone therapy is more beneficial in treating non-thymomatous myasthenia gravis than prednisone therapy alone.
- Trial name
- NCT00294658
- Testing
- thymectomy plus prednisone, prednisone alone
- Where
- 70 sites in United States, Argentina and 16 more
- Volunteers
- 126 people
- Sponsor
- University of Alabama at Birmingham
Myasthenia Gravis
Application of Artificial Intelligence in Precision Medicine and Healthcare
This study aims to propose an intelligent health robot that utilizes remote intelligent robots to assist patients with disease-related issues, enabling them to address their problems promptly.
- Trial name
- NCT06879210
- Testing
- Mobile device.(phone)
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Yi Ting Yeh
Auto-immune Myasthenia
Education Program in Myasthenia
Patient therapeutic education (PTE) has become "a must" in the modern management of chronic diseases. Its main objective is to improve compliance with treatment and the application of preventive measures.
- Trial name
- MG-ETP (NCT04714658)
- Testing
- Therapeutic Education
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disease (NMOSD)
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory neurological autoimmune diseases.
- Conditions
- Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disease (NMOSD), Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Disorders (MOGAD), Myasthenia Gravis
- Trial name
- NCT06869278
- Testing
- LCAR-AIO T cells
- Where
- 3 sites in China
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Generalized Myasthenia Gravis
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
A randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.
- Trial name
- ADAPT (NCT03669588)
- Testing
- ARGX-113
- Where
- 66 sites in United States, Belgium and 14 more
- Volunteers
- 167 people
- Sponsor
- argenx
Myasthenia Gravis Exacerbations
A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations
This was a multicenter, prospective, open-label, non-controlled study to assess the efficacy and safety of an IV dose of 2 g/kg of IGIV-C in subjects with MG exacerbations.
- Trial name
- NCT02413580
- Testing
- IGIV-C
- Where
- 31 sites in Argentina, Belgium and 10 more
- Volunteers
- 49 people
- Sponsor
- Grifols Therapeutics LLC
Myasthenia Gravis
Mycophenolate Mofetil in Myasthenia Gravis
This is a prospective, multi-center, double-blind, placebo-controlled trial to determine the efficacy and safety of mycophenolate mofetil (MM) in combination with prednisone as the initial form of immunosuppression in patients…
- Trial name
- NCT00285350
- Testing
- mycophenolate mofetil
- Volunteers
- 80 people
- Sponsor
- FDA Office of Orphan Products Development
Myasthenia Gravis Generalised
A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.
This 2 arm study will provide optional continuation of double-blind treatment with CellCept or placebo, in patients with myasthenia gravis who have achieved good symptom control in study WX17798.
- Trial name
- NCT00408213
- Testing
- mycophenolate mofetil [CellCept]
- Where
- 16 sites in United States, France and 5 more
- Volunteers
- 136 people
- Sponsor
- Hoffmann-La Roche
Generalized Myasthenia Gravis
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).
- Trial name
- ziMyG (NCT06055959)
- Testing
- Zilucoplan
- Where
- 9 sites in United States, Italy and 3 more
- Volunteers
- 8 people
- Sponsor
- UCB Biopharma SRL